| Value | ₹104.1 Cr |
|---|---|
| Execution period | 18 months |
NSE filing, NSE: CHANDAN. Summary written from the filing by ALFA Finder's alert engine.
Chandan Healthcare Ltd: key numbers
- Share price
- ₹235.00
- Market cap
- ₹604.0 Cr
- Revenue (annual)
- ₹276.4 Cr
- Net profit (annual)
- ₹28.55 Cr
- P/E (TTM)
- 21.1×Sector 52.8×
- Promoter holding
- 47.20%-2.41% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandan Healthcare Ltd
All →Chandan Healthcare Other Announcement
Chandan Healthcare filed Crisil's monitoring report on warrant issue proceeds for the quarter ended September 30, 2026. Utilisation matched the stated objects with no deviation or delay.
Chandan Healthcare Annual General Meeting
Chandan Healthcare calls an EGM on 20 November 2026 to approve related party transactions, including director guarantees. E-voting runs 17 to 19 November 2026.
Chandan Healthcare Results Update
Chandan Healthcare's Q2 FY2027 revenue from diagnostics grew 46.66% YoY to Rs. 56.38 Crore, while its franchise network expanded to 685 locations.
- franchise expansion
- 410.0 franchises
Chandan Healthcare Debt & Borrowing: ₹5.22 Cr
Chandan Healthcare Limited secured a ₹5.22 Crore medical equipment loan from ICICI Bank for purchasing a 128-slice CT scanner.
- Value
- ₹5.22 Cr
- Execution
- 60 months
Chandan Healthcare Management Change
Mr. Vinod Jain has resigned from his position as Independent Director of Chandan Healthcare Limited, effective October 5, 2026, due to other professional commitments.
Chandan Healthcare Annual General Meeting
Chandan Healthcare Limited held its 23rd Annual General Meeting on September 30, 2026. The meeting covered routine business, including financial adoption and board appointments.
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.